What's next after Amylyx's ALS drug failure?

The latest disappointment in ALS research brought crushing news for patients and physicians.

March 8, 2024 Check out STAT+

Sponsored By

Amylyx Pharmaceuticals via AP STAT+ | Amylyx ALS drug failure leaves patients, advocates, and researchers reeling — and wondering what's next The failure of Relyvrio, an ALS drug made by Amylyx Pharmaceuticals, raises tough questions for the patients, disease advocates, and the FDA. By Adam Feuerstein and Damian Garde STAT+ | In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug While Lilly had previously said a regulatory decision was expected by the end of 2023, it had already pushed that back to the first quarter of 2024. By Andrew Joseph STAT+ | Obesity drug Wegovy gets FDA approval to add cardiovascular benefits on its label The label expansion could boost demand and insurance coverage for Novo Nordisk's popular but expensive obesity drug. By Elaine Chen Molly Ferguson for STAT STAT+ | Biden's SOTU highlights pharma's biggest political problem: It is terrifyingly, awfully alone Pharma used to rely on the support of pro-business Republicans, with occasional backing from pro-science Democrats in some states. No more. By Matthew Herper STAT+ | UnitedHealth gives timeline for Change restoration: payments up by late next week UnitedHealth Group aims to restore Change Healthcare systems within the next two weeks, it said in an update. By Tara Bannow STAT+ | IVF doctors demand full details on fluid that grows embryos amid CooperSurgical lawsuits In vitro fertilization relies on embryos grown in nutrient-rich culture media. IVF doctors say they don't have full details on its contents. By Lizzy Lawrence Photo illustration: Casey Shenery for STAT A disabled artist's journey from 'Oh, sorry' to social justice activism Born with cerebral palsy, Sonya Rio-Glick challenged herself to stop apologizing for everything. Now she's an artist and activist. By Isabella Cueto STAT+ | Opinion: It's time to rethink everything about our approach to psychiatric drug development We are at risk of killing green shoots in psychiatric drug development if we don't rethink everything about our current approach. By Amit Etkin

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser